JP2015502400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502400A5 JP2015502400A5 JP2014548324A JP2014548324A JP2015502400A5 JP 2015502400 A5 JP2015502400 A5 JP 2015502400A5 JP 2014548324 A JP2014548324 A JP 2014548324A JP 2014548324 A JP2014548324 A JP 2014548324A JP 2015502400 A5 JP2015502400 A5 JP 2015502400A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- liposome
- glycero
- chlorite
- phosphocholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 89
- 239000002502 liposome Substances 0.000 claims 52
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims 32
- 150000002632 lipids Chemical class 0.000 claims 30
- 238000000034 method Methods 0.000 claims 27
- 229910001919 chlorite Inorganic materials 0.000 claims 23
- 229910052619 chlorite group Inorganic materials 0.000 claims 23
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000000232 Lipid Bilayer Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- TYAQXZHDAGZOEO-KXQOOQHDSA-N 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC TYAQXZHDAGZOEO-KXQOOQHDSA-N 0.000 claims 2
- UIXXHROAQSBBOV-PSXMRANNSA-N 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC UIXXHROAQSBBOV-PSXMRANNSA-N 0.000 claims 2
- MZWGYEJOZNRLQE-KXQOOQHDSA-N 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC MZWGYEJOZNRLQE-KXQOOQHDSA-N 0.000 claims 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- RZBMBMLIIRIAMH-LDLOPFEMSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(octadecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCCCC)=O RZBMBMLIIRIAMH-LDLOPFEMSA-N 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008344 egg yolk phospholipid Substances 0.000 claims 2
- 229940068998 egg yolk phospholipid Drugs 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003408 sphingolipids Chemical class 0.000 claims 2
- HRTBOPUWPUXROO-VCZQVZGSSA-N (2-{[(2r)-2,3-bis(docosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC HRTBOPUWPUXROO-VCZQVZGSSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- ATHVAWFAEPLPPQ-VRDBWYNSSA-N 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC ATHVAWFAEPLPPQ-VRDBWYNSSA-N 0.000 claims 1
- BYSIMVBIJVBVPA-RRHRGVEJSA-N 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC BYSIMVBIJVBVPA-RRHRGVEJSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- SXZWBNWTCVLZJN-NMIJJABPSA-N N-tricosanoylsphing-4-enine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC SXZWBNWTCVLZJN-NMIJJABPSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 claims 1
- BPHQZTVXXXJVHI-IADGFXSZSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-IADGFXSZSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000007012 clinical effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 150000002190 fatty acyls Chemical group 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- LLCSXHMJULHSJN-LWOQYNTDSA-N sn-glycero-3-phosphoglycerol Chemical compound OCC(O)COP(O)(=O)OC[C@H](O)CO LLCSXHMJULHSJN-LWOQYNTDSA-N 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- YNQYZBDRJZVSJE-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl 2,3-di(octadecanoyloxy)propyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC YNQYZBDRJZVSJE-UHFFFAOYSA-M 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579326P | 2011-12-22 | 2011-12-22 | |
| US61/579,326 | 2011-12-22 | ||
| PCT/IB2012/057645 WO2013093891A1 (en) | 2011-12-22 | 2012-12-21 | Liposomal chlorite or chlorate compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502400A JP2015502400A (ja) | 2015-01-22 |
| JP2015502400A5 true JP2015502400A5 (enExample) | 2015-11-05 |
Family
ID=47630448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548324A Pending JP2015502400A (ja) | 2011-12-22 | 2012-12-21 | リポソームの亜塩素酸塩または塩素酸塩組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130177629A1 (enExample) |
| EP (1) | EP2793860A1 (enExample) |
| JP (1) | JP2015502400A (enExample) |
| CN (1) | CN104125826A (enExample) |
| AU (1) | AU2012297589C1 (enExample) |
| BR (1) | BR112014015333A2 (enExample) |
| CA (1) | CA2857604A1 (enExample) |
| IN (1) | IN2014DN05866A (enExample) |
| MX (1) | MX2014007664A (enExample) |
| RU (1) | RU2014130080A (enExample) |
| WO (1) | WO2013093891A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006322076C1 (en) | 2005-12-08 | 2013-11-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| WO2014037927A1 (en) * | 2012-09-10 | 2014-03-13 | Nuvo Research Gmbh | Chlorate compositions and use of chlorate for treating radiation exposure |
| ES2743039T3 (es) | 2012-11-29 | 2020-02-18 | Insmed Inc | Formulaciones de vancomicina estabilizada |
| US9603799B2 (en) | 2013-03-15 | 2017-03-28 | Htd Biosystems Inc. | Liposomal vaccine adjuvants and methods of making and using same |
| US20140271815A1 (en) * | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
| EP3466432B1 (en) | 2014-05-15 | 2020-07-08 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| JP6900596B2 (ja) * | 2015-08-20 | 2021-07-07 | フリードリッヒ − ヴィルヘルム キューネ | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
| TWI719105B (zh) | 2016-01-04 | 2021-02-21 | 中央硏究院 | 基於酯化/皂化用於微脂體負載之方法 |
| US20190142864A1 (en) * | 2017-10-11 | 2019-05-16 | California Institute Of Technology | Methods and systems, for interfering with viability of bacteria and related antimicrobials and compositions |
| EP3752833B1 (en) * | 2018-02-15 | 2025-08-13 | Yeditepe Universitesi | Exosome isolation method by two phase fluid system |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| CN110563829B (zh) * | 2019-09-17 | 2021-03-26 | 中国人民解放军国防科技大学 | 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用 |
| CN112716973A (zh) * | 2019-10-28 | 2021-04-30 | 卢序 | 一种降低细胞还原应激的氧化剂的用途 |
| TR202012260A2 (tr) * | 2020-08-05 | 2020-10-21 | Emin Zuemruetdal | Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu |
| CA3253808A1 (en) * | 2022-05-19 | 2023-11-23 | Neuvivo Inc | BIOMARKERS OF NEURODEGENERATIVE DISEASES |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DE3213389A1 (de) | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
| US4551288A (en) | 1982-08-16 | 1985-11-05 | Sandoz, Inc. | Processes for the preparation of liposome drug delivery systems |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4574084A (en) | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| DE3515745A1 (de) | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| JPH0751496B2 (ja) | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
| DE3625867C2 (de) | 1986-07-31 | 1995-10-19 | Elstner Erich F Prof Dr | Verwendung von Tetrachlordecaoxid in der Ophthalmologie |
| US4781871A (en) | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
| US4752425A (en) | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
| US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| WO1988007850A1 (en) | 1987-04-16 | 1988-10-20 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
| US5049390A (en) | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| US4851222A (en) | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
| US5269979A (en) | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US5190822A (en) | 1990-04-20 | 1993-03-02 | Fuji Photo Film Co., Ltd. | Surface-modifiable liposome and process for producing surface-modified liposome |
| US5206027A (en) | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
| WO1992007959A1 (en) | 1990-11-05 | 1992-05-14 | Biowhittaker Inc. | Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| JPH06206825A (ja) | 1992-12-11 | 1994-07-26 | Nippon Rooshiyon Kk | 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤 |
| EP0616801B1 (de) | 1993-03-24 | 1998-05-27 | Novartis AG | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
| CA2179014C (en) | 1993-12-17 | 2003-07-29 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US6110666A (en) | 1994-06-09 | 2000-08-29 | Medical Research Council | Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure |
| US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| JP3735921B2 (ja) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | ＧＰＩｂ・脂質複合体およびその用途 |
| US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| ES2217582T3 (es) | 1997-10-06 | 2004-11-01 | Oxo Chemie Ag | Uso de una disolucion de clorito quimicamente estabilizada para inhibir una respuesta inmunitaria especifica de un antigeno. |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| AU759164C (en) | 1997-11-19 | 2007-03-29 | Georgetown University | Targeted liposome gene delivery |
| WO1999041403A1 (en) | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
| US6132702A (en) | 1998-02-27 | 2000-10-17 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6077502A (en) | 1998-02-27 | 2000-06-20 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6251372B1 (en) | 1998-02-27 | 2001-06-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6350438B1 (en) | 1998-02-27 | 2002-02-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
| MXPA01003507A (es) * | 1998-10-08 | 2002-06-26 | Hampar L Karagoezian | Antimicrobiano sinergico, preparaciones dermatologicas y oftalmicas que contienen clorito y peroxido de hidrogeno. |
| WO2000019981A1 (en) | 1998-10-08 | 2000-04-13 | Karagoezian Hampar L | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide |
| JP2001002592A (ja) | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
| IL148189A0 (en) | 1999-08-18 | 2002-09-12 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
| WO2001017030A1 (en) | 1999-08-27 | 2001-03-08 | Macronix America, Inc. | Non-volatile memory structure for twin-bit storage and methods of making same |
| US20070104798A1 (en) * | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| JP2003514843A (ja) | 1999-11-24 | 2003-04-22 | ザ リポソーム カンパニー、インコーポレーテッド | モジュラー標的化リポソーム送達システム |
| CA2394717C (en) | 1999-12-30 | 2011-05-17 | Judith K. Gwathmey | Iron chelator delivery system |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US7101985B2 (en) | 2001-11-20 | 2006-09-05 | Baylor College Of Medicine | Methods and compositions in checkpoint signaling |
| US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| KR20030072766A (ko) * | 2002-03-06 | 2003-09-19 | (주)인터커머스 | 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법 |
| US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
| JP3415131B1 (ja) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8765808B2 (en) * | 2005-03-23 | 2014-07-01 | Chs Pharma, Inc. | Treatment or prevention of cancer and precancerous disorders |
| AU2006272343B2 (en) | 2005-07-21 | 2012-09-13 | Nuvo Research Ag | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
| US8067035B2 (en) * | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| EP1971426A1 (de) | 2006-01-11 | 2008-09-24 | P & W Invest Vermögensverwaltungsgesellschaft mbH | Hüllenmembran zur abgabe eines eingeschlossenen wirkstoffs, ein verfahren zur herstellung sowie deren verwendung |
| US8252343B2 (en) | 2007-06-01 | 2012-08-28 | Nuvo Research Ag | Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| US20110052655A1 (en) | 2007-08-08 | 2011-03-03 | Wilson Kurt Whitekettle | Methods and vesicles for controlling protozoa |
| EP2449114B9 (en) * | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US20110177147A1 (en) | 2010-01-21 | 2011-07-21 | General Electric Company | Stable biocidal delivery systems |
-
2012
- 2012-12-21 CA CA2857604A patent/CA2857604A1/en not_active Abandoned
- 2012-12-21 CN CN201280070434.8A patent/CN104125826A/zh active Pending
- 2012-12-21 MX MX2014007664A patent/MX2014007664A/es unknown
- 2012-12-21 WO PCT/IB2012/057645 patent/WO2013093891A1/en not_active Ceased
- 2012-12-21 EP EP12820937.6A patent/EP2793860A1/en not_active Withdrawn
- 2012-12-21 US US13/724,963 patent/US20130177629A1/en not_active Abandoned
- 2012-12-21 IN IN5866DEN2014 patent/IN2014DN05866A/en unknown
- 2012-12-21 BR BR112014015333A patent/BR112014015333A2/pt not_active IP Right Cessation
- 2012-12-21 JP JP2014548324A patent/JP2015502400A/ja active Pending
- 2012-12-21 AU AU2012297589A patent/AU2012297589C1/en not_active Ceased
- 2012-12-21 RU RU2014130080A patent/RU2014130080A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502400A5 (enExample) | ||
| RU2014130080A (ru) | Липосомальные композиции хлоритов или хлоратов | |
| Al-Ahmady et al. | Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia | |
| Avnir et al. | Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids | |
| JP6449848B2 (ja) | 水性及び非水性区画の両方におけるリポソーム組成物による制御薬物放出プロファイルの操作 | |
| CN102223878A (zh) | 包含鞘磷脂的脂质体系统 | |
| JP2015515992A5 (enExample) | ||
| BR112020001411A2 (pt) | composição farmacêutica e método para tratar uma doença respiratória | |
| JP7173615B2 (ja) | 徐放性麻酔組成物及びその調製方法 | |
| TW201841622A (zh) | 熱塑性奈米粒子及其製法 | |
| CN115243677A (zh) | 用于递送治疗剂的生物可降解药物洗脱栓塞颗粒 | |
| Maheswaran et al. | Liposomal drug delivery systems—a review | |
| JP6533297B2 (ja) | 表皮成長因子とリポソームのハイブリッド型多層ナノ構造体及びその製造方法 | |
| CN107708670A (zh) | 磷脂包衣的治疗剂纳米颗粒和有关的方法 | |
| Sanarova et al. | Liposome drug delivery | |
| KR20070011331A (ko) | 리포솜 제제 | |
| EP2398463A1 (en) | A method for amphiphilic drug loading in liposomes by ion gradient | |
| CN105517538A (zh) | 镁-脂质体 | |
| Matole et al. | Need of liposomes as a novel drug delivery system | |
| CN103764122A (zh) | 包含至少一种胆甾醇衍生物的脂质体 | |
| JP2000302685A (ja) | 抗腫瘍薬含有リポソーム製剤 | |
| RU2791481C2 (ru) | Анестетические композиции с замедленным высвобождением и способы их получения | |
| KR102611802B1 (ko) | 인슐린유사성장인자와 리포좀의 하이브리드형 다중층 나노구조체 및 그 제조방법 | |
| C Santos et al. | Thermolabile liposomes: a controlled release delivery tool in diagnosis/therapy in experimental pulmonary oedema | |
| JP2022505378A (ja) | 免疫調節剤を含む徐放性医薬組成物およびその使用 |